Artículo

Ramakrishnan, S.; Granger, V.; Rak, M.; Hu, Q.; Attwood, K.; Aquila, L.; Krishnan, N.; Osiecki, R.; Azabdaftari, G.; Guru, K.; Chatta, G.; Gueron, G.; McNally, L.; Ohm, J.; Wang, J.; Woloszynska, A. "Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer" (2019) Cell Death and Differentiation
Estamos trabajando para incorporar este artículo al repositorio
Consulte el artículo en la página del editor
Consulte la política de Acceso Abierto del editor

Abstract:

Lysine-specific demethylase 6A (KDM6A) and members of the Switch/Sucrose Non-Fermentable (SWI/SNF) family are known to counteract the activity of Enhancer of Zeste Homolog 2 (EZH2), which is often overexpressed and is associated with poor prognosis in muscle-invasive bladder cancer. Here we provide evidence that alterations in chromatin modifying enzymes, including KDM6A and members of the SWI/SNF complex, are frequent in muscle-invasive bladder cancer. We exploit the loss of function mutations in KDM6A and SWI/SNF complex to make bladder cancer cells susceptible to EZH2-based epigenetic therapy that activates an immune response to drive tumor cell differentiation and death. We reveal a novel mechanism of action of EZH2 inhibition, alone and in combination with cisplatin, which induces immune signaling with the largest changes observed in interferon gamma (IFN-γ). This upregulation is a result of activated natural killer (NK) signaling as demonstrated by the increase in NK cell-associated genes MIP-1α, ICAM1, ICAM2, and CD86 in xenografts treated with EZH2 inhibitors. Conversely, EZH2 inhibition results in decreased expression of pluripotency markers, ALDH2 and CK5, and increased cell death. Our results reveal a novel sensitivity of muscle-invasive bladder cancer cells with KMD6A and SWI/SNF mutations to EZH2 inhibition alone and in combination with cisplatin. This sensitivity is mediated through increased NK cell-related signaling resulting in tumor cell differentiation and cell death. © 2019, ADMC Associazione Differenziamento e Morte Cellulare.

Registro:

Documento: Artículo
Título:Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer
Autor:Ramakrishnan, S.; Granger, V.; Rak, M.; Hu, Q.; Attwood, K.; Aquila, L.; Krishnan, N.; Osiecki, R.; Azabdaftari, G.; Guru, K.; Chatta, G.; Gueron, G.; McNally, L.; Ohm, J.; Wang, J.; Woloszynska, A.
Filiación:Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
Department of Cell Biology, Jagiellonian University, Krakow, 31-007, Poland
Department of Bioinformatics and BioStatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
Child Jesus Hospital, Warsaw, 02-005, Poland
Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
Department of Medicine-GU Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, United States
Department of Biological Chemistry, University of Buenos Aires, IQUIBICEN-CONICET, Intendente Guiraldes 2160, CABA, Buenos Aires, 1428, Argentina
Department of Cancer Biology, Wake Forest Comprehensive Cancer Center, Winston-Salem, NC 27157, United States
Department of Cancer Genetics and Genomics, Comprehensive Cancer Center, Buffalo, NY 14263, United States
Año:2019
DOI: http://dx.doi.org/10.1038/s41418-019-0278-9
Título revista:Cell Death and Differentiation
Título revista abreviado:Cell Death Differ.
ISSN:13509047
CODEN:CDDIE
Registro:http://digital.bl.fcen.uba.ar/collection/paper/document/paper_13509047_v_n_p_Ramakrishnan

Referencias:

  • Nargund, A.M., Pham, C.G., Dong, Y., Wang, P.I., Osmangeyoglu, H.U., Xie, Y., The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear cell renal cell carcinoma (2017) Cell Rep, 18, pp. 2893-2906. , COI: 1:CAS:528:DC%2BC2sXkvFWrsr0%3D
  • Mathur, R., Alver, B.H., San Roman, A.K., Wilson, B.G., Wang, X., Agoston, A.T., ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice (2017) Nat Genet, 49, pp. 296-302. , COI: 1:CAS:528:DC%2BC28XitFWnsbfP
  • Aldiri, I., Ajioka, I., Xu, B., Zhang, J., Chen, X., Benavente, C., Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma (2015) Development, 142, pp. 4092-4106. , COI: 1:CAS:528:DC%2BC28XntFSmsbs%3D
  • Gao, S.B., Zheng, Q.F., Xu, B., Pan, C.B., Li, K.L., Zhao, Y., EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma (2014) Mol Cancer Res, 12, pp. 1388-1397. , COI: 1:CAS:528:DC%2BC2cXhslKns73O
  • Venkatesan, N., Wong, J.F., Tan, K.P., Chung, H.H., Yau, Y.H., Cukuroglu, E., EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms (2018) Oncogene, 37, pp. 461-477. , COI: 1:CAS:528:DC%2BC2sXhsFygu7%2FK
  • Beguelin, W., Teater, M., Gearhart, M.D., Calvo Fernandez, M.T., Goldstein, R.L., Cardenas, M.G., EZH2 and BCL6 cooperate to assemble CBX8-BCOR complex to repress bivalent promoters, mediate germinal center formation and lymphomagenesis (2016) Cancer Cell, 30, pp. 197-213. , COI: 1:CAS:528:DC%2BC28XhtlCrtLnL
  • Wilson, B.G., Wang, X., Shen, X., McKenna, E.S., Lemieux, M.E., Cho, Y.J., Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation (2010) Cancer Cell, 18, pp. 316-328. , COI: 1:CAS:528:DC%2BC3cXhtlSnu77J
  • Kia, S.K., Gorski, M.M., Giannakopoulos, S., Verrijzer, C.P., SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus (2008) Mol Cell Biol, 28, pp. 3457-3464. , COI: 1:CAS:528:DC%2BD1cXlvFeqs7g%3D
  • Karakashev, S., Zhu, H., Wu, S., Yokoyama, Y., Bitler, B.G., Park, P.H., CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity (2018) Nat Commun, 9
  • Januario, T., Ye, X., Bainer, R., Alicke, B., Smith, T., Haley, B., PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors (2017) Proc Natl Acad Sci USA, 114, pp. 12249-12254. , COI: 1:CAS:528:DC%2BC2sXhslemsr3K
  • Knutson, S.K., Warholic, N.M., Wigle, T.J., Klaus, C.R., Allain, C.J., Raimondi, A., Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 (2013) PNAS, 110, pp. 7922-7927. , COI: 1:CAS:528:DC%2BC3sXptFGrurw%3D
  • Bitler, B.G., Aird, K.M., Zhang, R., Epigenetic synthetic lethality in ovarian clear cell carcinoma: EZH2 and ARID1A mutations (2016) Mol Cell Oncol, 3
  • Kim, K.H., Kim, W., Howard, T.P., Vazquez, F., Tsherniak, A., Wu, J.N., SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 (2015) Nat Med, 21, p. 1491. , COI: 1:CAS:528:DC%2BC2MXhslKgt7nK
  • Chan-Penebre, E., Armstrong, K., Drew, A., Grassian, A.R., Feldman, I., Knutson, S.K., Selective killing of SMARCA2- and SMARCA4-deficient small cell carcinoma of the ovary, hypercalcemic type cells by inhibition of EZH2: in vitro and in vivo preclinical models (2017) Mol Cancer Ther, 16, pp. 850-860. , COI: 1:CAS:528:DC%2BC2sXmvFemt74%3D
  • Morel, D., Almouzni, G., Soria, J.C., Postel-Vinay, S., Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism (2017) Ann Oncol, 28, pp. 254-269. , COI: 1:STN:280:DC%2BC1cvpsVOqtw%3D%3D, PID: 28426098
  • Liu, L., Xu, Z., Zhong, L., Wang, H., Jiang, S., Long, Q., Enhancer of zeste homolog 2 (EZH2) promotes tumour cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma (2016) BJU Int, 117, pp. 351-362. , COI: 1:CAS:528:DC%2BC28XpsFansg%3D%3D
  • Lv, Y.F., Yan, G.N., Meng, G., Zhang, X., Guo, Q.N., Enhancer of zeste homolog 2 silencing inhibits tumor growth and lung metastasis in osteosarcoma (2015) Sci Rep, 5. , COI: 1:CAS:528:DC%2BC2MXhsVKhs7vJ
  • Pawlyn, C., Bright, M.D., Buros, A.F., Stein, C.K., Walters, Z., Aronson, L.I., Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control (2017) Blood Cancer J, 7. , COI: 1:STN:280:DC%2BC1cvjtFeisA%3D%3D
  • Agger, K., Cloos, P.A.C., Christensen, J., Pasini, D., Rose, S., Rappsilber, J., UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development (2007) Nature, 449, pp. 731-734. , COI: 1:CAS:528:DC%2BD2sXhtFChu77P
  • Shpargel, K.B., Starmer, J., Wang, C., Ge, K., Magnuson, T., UTX-guided neural crest function underlies craniofacial features of Kabuki syndrome (2017) PNAS, 114, pp. E9046-E9055. , COI: 1:CAS:528:DC%2BC2sXhs1aju7nK
  • Hong, S., Cho, Y.W., Yu, L.R., Yu, H., Veenstra, T.D., Ge, K., Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases (2007) PNAS, 104, pp. 18439-18444. , COI: 1:CAS:528:DC%2BD2sXhtl2ku7rI
  • Ler, L.D., Ghosh, S., Chai, X., Thike, A.A., Heng, H.L., Siew, E.Y., Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 (2017) Sci Transl Med, 9. , eaai8312
  • Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder (2011) Nat Genet, 43, p. 875. , COI: 1:CAS:528:DC%2BC3MXpvVOmurg%3D
  • Comprehensive molecular characterization of urothelial bladder carcinoma (2014) Nature, 507, pp. 315-322
  • Lee, S.R., Roh, Y.G., Kim, S.K., Lee, J.S., Seol, S.Y., Lee, H.H., Activation of EZH2 and SUZ12 regulated by E2F1 predicts the disease progression and aggressive characteristics of bladder cancer (2015) Clin Cancer Res, 21, pp. 5391-5403. , COI: 1:CAS:528:DC%2BC2MXhvFKlurrN
  • Warrick, J.I., Raman, J.D., Kaag, M., Bruggeman, T., Cates, J., Clark, P., Enhancer of zeste homolog 2 (EZH2) expression in bladder cancer (2016) Urol Oncol, 34, pp. 258.e251-256
  • Tuominen, V.J., Ruotoistenmaki, S., Viitanen, A., Jumppanen, M., Isola, J., ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 (2010) Breast Cancer Res, 12
  • https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm559300.htm; Powles, T., O’Donnell, P.H., Massard, C., Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: Updated results from a phase 1/2 open-label study (2017) JAMA Oncol, 3
  • Sonpavde, G., Sternberg, C.N., Rosenberg, J.E., Hahn, N.M., Galsky, M.D., Vogelzang, N.J., Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium (2010) Lancet Oncol, 11, pp. 861-870. , COI: 1:CAS:528:DC%2BC3cXhtFWqsrzN
  • Wilson, B.G., Roberts, C.W.M., SWI/SNF nucleosome remodellers and cancer (2011) Nat Rev Cancer, 11, p. 481. , COI: 1:CAS:528:DC%2BC3MXntFKrsLw%3D
  • Bracken, A.P., Dietrich, N., Pasini, D., Hansen, K.H., Helin, K., Genome-wide mapping of polycomb target genes unravels their roles in cell fate transitions (2006) Genes Dev, 20, pp. 1123-1136. , COI: 1:CAS:528:DC%2BD28XkslCjsbs%3D
  • Bitler, B.G., Aird, K.M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A.V., Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers (2015) Nat Med, 21, p. 231. , COI: 1:CAS:528:DC%2BC2MXivVSit7k%3D
  • Forbes, S.A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., COSMIC: exploring the world’s knowledge of somatic mutations in human cancer (2015) Nucleic Acids Res, 43 (Database issue), pp. D805-D811. , COI: 1:CAS:528:DC%2BC2sXhtV2itr3F
  • Bowman, K.J., Al-Moneef, M.M., Sherwood, B.T., Colquhoun, A.J., Goddard, J.C., Griffiths, T.R., Comet assay measures of DNA damage are predictive of bladder cancer cell treatment sensitivity in vitro and outcome in vivo (2014) Int J Cancer, 134, pp. 1102-1111. , COI: 1:CAS:528:DC%2BC3sXhsFOgu73J
  • Ferreira-Teixeira, M., Paiva-Oliveira, D., Parada, B., Alves, V., Sousa, V., Chijioke, O., Natural killer cell-based adoptive immunotherapy eradicates and drives differentiation of chemoresistant bladder cancer stem-like cells (2016) BMC Med, 14
  • Li, L., Li, W., Wang, C., Yan, X., Wang, Y., Niu, C., Adoptive transfer of natural killer cells in combination with chemotherapy improves outcomes of patients with locally advanced colon carcinoma (2018) Cytotherapy, 20, pp. 134-148. , COI: 1:CAS:528:DC%2BC2sXhs1yrt7jJ
  • Jin, X., Kim, L.J.Y., Wu, Q., Wallace, L.C., Prager, B.C., Sanvoranart, T., Targeting glioma stem cells through combined BMI1 and EZH2 inhibition (2017) Nat Med, 23, pp. 1352-1361. , COI: 1:CAS:528:DC%2BC2sXhs1aisrzJ, PID: 29035367
  • Liu, H., Sun, Q., Sun, Y., Zhang, J., Yuan, H., Pang, S., MELK and EZH2 cooperate to regulate medulloblastoma cancer stem-like cell proliferation and differentiation (2017) Mol Cancer Res, 15, pp. 1275-1286
  • Rizzo, S., Hersey, J.M., Mellor, P., Dai, W., Santos-Silva, A., Liber, D., Ovarian cancer stem cell like side populations are enriched following chemotherapy and overexpress EZH2 (2011) Mol Cancer Ther, 10, pp. 325-335. , COI: 1:CAS:528:DC%2BC3MXhs1ylsLg%3D
  • Wang, L., Liu, X., Ren, Y., Zhang, J., Chen, J., Zhou, W., Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity (2017) Cell Death Dis, 8. , COI: 1:CAS:528:DC%2BC2sXmtVCrs7w%3D
  • Kozlowska, A.K., Topchyan, P., Kaur, K., Tseng, H.C., Teruel, A., Hiraga, T., Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs (2017) J Cancer, 8, pp. 537-554. , COI: 1:CAS:528:DC%2BC1cXhtl2msbbP
  • Van Batavia, J., Yamany, T., Molotkov, A., Dan, H., Mansukhani, M., Batourina, E., Bladder cancers arise from distinct urothelial sub-populations (2014) Nat Cell Biol, 16, pp. 982-991. , 981-5
  • Chen, Y., Zhou, B., Chen, D., USP21 promotes cell proliferation and metastasis through suppressing EZH2 ubiquitination in bladder carcinoma (2017) Onco Targets Ther, 10, pp. 681-689. , COI: 1:CAS:528:DC%2BC1cXhsFeltLnL
  • Karantanos, T., Boussiotis, V.A., JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function (2016) Transl Cancer Res, 5, pp. S1208-s1211
  • Yan, J., Li, B., Lin, B., Lee, P.T., Chung, T.H., Tan, J., EZH2 phosphorylation by JAK3 mediates a switch to noncanonical function in natural killer/T-cell lymphoma (2016) Blood, 128, pp. 948-958. , COI: 1:CAS:528:DC%2BC28XhslOkt73E
  • Santos, M., Martinez-Fernandez, M., Duenas, M., Garcia-Escudero, R., Alfaya, B., Villacampa, F., In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer (2014) Cancer Res, 74, pp. 6565-6577. , COI: 1:CAS:528:DC%2BC2cXhvFWks77N
  • Wee, Z.N., Li, Z., Lee, P.L., Lee, S.T., Lim, Y.P., Yu, Q., EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer (2014) Cell Rep, 8, pp. 204-216. , COI: 1:CAS:528:DC%2BC2cXhtVCjurzJ
  • Böttcher, J.P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control (2018) Cell, 172, pp. 1022-1037.e1014
  • Noman, M.Z., Berchem, G., Janji, B., Targeting autophagy blocks melanoma growth by bringing natural killer cells to the tumor battlefield (2018) Autophagy, 14, pp. 730-732
  • Guerra, N., Tan, Y.X., Joncker, N.T., Choy, A., Gallardo, F., Xiong, N., NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy (2008) Immunity, 28, pp. 571-580. , COI: 1:CAS:528:DC%2BD1cXkvV2itL8%3D
  • Bugide, S., Green, M.R., Wajapeyee, N., Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells (2018) Proc Natl Acad Sci USA, 115, pp. E3509-E3518
  • Cribbs, A., Hookway, E.S., Wells, G., Lindow, M., Obad, S., Oerum, H., Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells (2018) J Biol Chem, 293, pp. 2422-2437. , COI: 1:CAS:528:DC%2BC1cXivVCktr0%3D
  • Yin, J., Leavenworth, J.W., Li, Y., Luo, Q., Xie, H., Liu, X., Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity (2015) PNAS, 112, pp. 15988-15993. , COI: 1:CAS:528:DC%2BC2MXitVWjtLvM
  • Ikeda, H., Old, L.J., Schreiber, R.D., The roles of IFN gamma in protection against tumor development and cancer immunoediting (2002) Cytokine Growth Factor Rev, 13, pp. 95-109. , COI: 1:CAS:528:DC%2BD38XitFWhsrs%3D
  • Cany, J., Roeven, M.W.H., Hoogstad-van Evert, J.S., Hobo, W., Maas, F., Franco Fernandez, R., Decitabine enhances targeting of AML cells by CD34(+) progenitor-derived NK cells in NOD/SCID/IL2Rg(null) mice (2018) Blood, 131, pp. 202-214. , COI: 1:CAS:528:DC%2BC1cXhs1Cqsr7J
  • Baragano Raneros, A., Martin-Palanco, V., Fernandez, A.F., Rodriguez, R.M., Fraga, M.F., Lopez-Larrea, C., Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia (2015) Genes Immun, 16, pp. 71-82. , COI: 1:CAS:528:DC%2BC2cXhvFCiur7O
  • Zingg, D., Arenas-Ramirez, N., Sahin, D., Rosalia, R.A., Antunes, A.T., Haeusel, J., The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy (2017) Cell Rep, 20, pp. 854-867. , COI: 1:CAS:528:DC%2BC2sXht1Gis7fP
  • Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy (2015) Nature, 527, pp. 249-253. , COI: 1:CAS:528:DC%2BC2MXhslOrtLjI
  • Tang, S.H., Huang, H.S., Wu, H.U., Tsai, Y.T., Chuang, M.J., Yu, C.P., Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo (2014) Oncotarget, 5, pp. 10342-10355. , PID: 25431950
  • Kim, S.H., Joshi, K., Ezhilarasan, R., Myers, T.R., Siu, J., Gu, C., EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner (2015) Stem Cell Rep, 4, pp. 226-238. , COI: 1:CAS:528:DC%2BC2MXhtVGms7o%3D
  • Chen, J.F., Luo, X., Xiang, L.S., Li, H.T., Zha, L., Li, N., EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/beta-catenin signaling (2016) Oncotarget, 7, pp. 41540-41558. , PID: 27172794
  • Chan, K.S., Molecular pathways: targeting cancer stem cells awakened by chemotherapy to abrogate tumor repopulation (2016) Clin Cancer Res, 22, pp. 802-806. , COI: 1:CAS:528:DC%2BC28XivFGmsbg%3D
  • Chen, Z., Zhu, P., Zhang, Y., Liu, Y., He, Y., Zhang, L., Enhanced sensitivity of cancer stem cells to chemotherapy using functionalized mesoporous silica nanoparticles (2016) Mol Pharm, 13, pp. 2749-2759. , COI: 1:CAS:528:DC%2BC28XhtVGjtLrP

Citas:

---------- APA ----------
Ramakrishnan, S., Granger, V., Rak, M., Hu, Q., Attwood, K., Aquila, L., Krishnan, N.,..., Woloszynska, A. (2019) . Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death and Differentiation.
http://dx.doi.org/10.1038/s41418-019-0278-9
---------- CHICAGO ----------
Ramakrishnan, S., Granger, V., Rak, M., Hu, Q., Attwood, K., Aquila, L., et al. "Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer" . Cell Death and Differentiation (2019).
http://dx.doi.org/10.1038/s41418-019-0278-9
---------- MLA ----------
Ramakrishnan, S., Granger, V., Rak, M., Hu, Q., Attwood, K., Aquila, L., et al. "Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer" . Cell Death and Differentiation, 2019.
http://dx.doi.org/10.1038/s41418-019-0278-9
---------- VANCOUVER ----------
Ramakrishnan, S., Granger, V., Rak, M., Hu, Q., Attwood, K., Aquila, L., et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death Differ. 2019.
http://dx.doi.org/10.1038/s41418-019-0278-9